Nordic MDS-group

Introduction
Coordinators
Members
Studies
Publications
Diagnosis and prognosis
Nordic Care Programme
Meeting Calendar
Contact information

Patient informations

Danish Dk
Finish Fi
Icelandic Is
Norwegian No
Swedish Se


Members only
User name:  

Password:  

Guidelines for the diagnosis and treatment of the myelodysplastic syndromes

The myelodysplastic syndromes (MDS) encompass a heterogeneous group of malignant bone marrow diseases characterized by ineffective, dysplastic hematopoiesis with subsequent pancytopenia, and an increased risk for developing acute myeloid leukemia (AML). There is a vast variation in symptoms and prognosis. While some patients may live for decades with mild asymptomatic anemia, others present with profound pancytopenia and rapid progression towards AML. Several potential therapeutic options for MDS have been evaluated in clinical trials, but the majority of these have shown only moderate efficacy. Moreover, there are relatively few randomized controlled trials to support decision-making for the individual patient.

The Nordic MDS group (NMDSG) is a pan-Nordic organisation, which has conducted clinical trials in MDS since 1985. NMDSG decided, in 2003, to write a Care Programme for MDS, which will be published on-line at the website www.nordicmds.org. The Care Programme is written for health professionals with a speciality or an interest in hematology. It will be updated at least yearly, and we therefore recommend colleagues to use the on-line version, rather than to print and copy paper versions of the document.

Nordic MDS Group
Revised version 2007-01-20

Guidelines_version_November 2006

© 2004-2008 nordicmds.org